Franz X. Vollenweider - Publications

Affiliations: 
Psychiatry Universität Zürich, Zürich, ZH, Switzerland 
Area:
Neuroimaging, Hallucinogens, ASC

123 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Smigielski L, Kometer M, Scheidegger M, Krähenmann R, Huber T, Vollenweider FX. Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat. Scientific Reports. 9: 14914. PMID 31649304 DOI: 10.1038/s41598-019-50612-3  0.8
2019 Pokorny T, Duerler P, Seifritz E, Vollenweider FX, Preller KH. LSD acutely impairs working memory, executive functions, and cognitive flexibility, but not risk-based decision-making. Psychological Medicine. 1-10. PMID 31500679 DOI: 10.1017/S0033291719002393  0.56
2019 Smigielski L, Scheidegger M, Kometer M, Vollenweider FX. Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects. Neuroimage. PMID 30965131 DOI: 10.1016/j.neuroimage.2019.04.009  0.8
2019 Dornbierer DA, Kometer M, Von Rotz R, Studerus E, Gertsch J, Gachet MS, Vollenweider FX, Seifritz E, Bosch OG, Quednow BB. Effects of gamma-hydroxybutyrate on neurophysiological correlates of performance and conflict monitoring. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. PMID 30824339 DOI: 10.1016/j.euroneuro.2019.02.004  0.8
2019 Preller KH, Razi A, Zeidman P, Stämpfli P, Friston KJ, Vollenweider FX. Effective connectivity changes in LSD-induced altered states of consciousness in humans. Proceedings of the National Academy of Sciences of the United States of America. PMID 30692255 DOI: 10.1073/pnas.1815129116  0.56
2018 Preller KH, Burt JB, Ji JL, Schleifer CH, Adkinson BD, Stämpfli P, Seifritz E, Repovs G, Krystal JH, Murray JD, Vollenweider FX, Anticevic A. Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor. Elife. 7. PMID 30355445 DOI: 10.7554/eLife.35082  0.56
2018 Preller KH, Schilbach L, Pokorny T, Flemming J, Seifritz E, Vollenweider FX. Role of the 5-HTreceptor in self- and other-initiated social interaction in LSD-induced states - a pharmacological fMRI study. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. PMID 29555857 DOI: 10.1523/JNEUROSCI.1939-17.2018  0.56
2017 Kraehenmann R, Pokorny D, Aicher H, Preller KH, Pokorny T, Bosch OG, Seifritz E, Vollenweider FX. LSD Increases Primary Process Thinking via Serotonin 2A Receptor Activation. Frontiers in Pharmacology. 8: 814. PMID 29167644 DOI: 10.3389/fphar.2017.00814  0.56
2017 Barrett FS, Preller KH, Herdener M, Janata P, Vollenweider FX. Serotonin 2A Receptor Signaling Underlies LSD-induced Alteration of the Neural Response to Dynamic Changes in Music. Cerebral Cortex (New York, N.Y. : 1991). 1-12. PMID 29028939 DOI: 10.1093/cercor/bhx257  0.56
2017 Lewis CR, Preller KH, Kraehenmann R, Michels L, Stämpfli P, Vollenweider FX. Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow. Neuroimage. PMID 28711736 DOI: 10.1016/j.neuroimage.2017.07.020  0.56
2017 Preller KH, Vollenweider FX. Erratum to: Phenomenology, Structure, and Dynamic of Psychedelic States. Current Topics in Behavioral Neurosciences. PMID 28710675 DOI: 10.1007/7854_2017_477  0.56
2017 Pokorny T, Preller KH, Kometer M, Dziobek I, Vollenweider FX. Effect of psilocybin on empathy and moral decision-making. The International Journal of Neuropsychopharmacology. PMID 28637246 DOI: 10.1093/ijnp/pyx047  0.8
2017 von Rotz R, Kometer M, Dornbierer D, Gertsch J, Salomé Gachet M, Vollenweider FX, Seifritz E, Bosch OG, Quednow BB. Neuronal oscillations and synchronicity associated with gamma-hydroxybutyrate during resting-state in healthy male volunteers. Psychopharmacology. PMID 28429067 DOI: 10.1007/s00213-017-4603-z  0.8
2017 Kraehenmann R, Pokorny D, Vollenweider L, Preller KH, Pokorny T, Seifritz E, Vollenweider FX. Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation. Psychopharmacology. PMID 28386699 DOI: 10.1007/s00213-017-4610-0  0.56
2017 Preller KH, Herdener M, Pokorny T, Planzer A, Kraehenmann R, Stämpfli P, Liechti ME, Seifritz E, Vollenweider FX. The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation. Current Biology : Cb. PMID 28132813 DOI: 10.1016/j.cub.2016.12.030  0.6
2016 Preller KH, Vollenweider FX. Phenomenology, Structure, and Dynamic of Psychedelic States. Current Topics in Behavioral Neurosciences. PMID 28025814 DOI: 10.1007/7854_2016_459  0.56
2016 Kometer M, Vollenweider FX. Serotonergic Hallucinogen-Induced Visual Perceptual Alterations. Current Topics in Behavioral Neurosciences. PMID 27900674 DOI: 10.1007/7854_2016_461  0.8
2016 Preller KH, Pokorny T, Hock A, Kraehenmann R, Stämpfli P, Seifritz E, Scheidegger M, Vollenweider FX. Effects of serotonin 2A/1A receptor stimulation on social exclusion processing. Proceedings of the National Academy of Sciences of the United States of America. PMID 27091970 DOI: 10.1073/pnas.1524187113  0.56
2016 Kraehenmann R, Schmidt A, Friston K, Preller KH, Seifritz E, Vollenweider FX. The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity. Neuroimage. Clinical. 11: 53-60. PMID 26909323 DOI: 10.1016/j.nicl.2015.08.009  0.56
2016 Pokorny T, Preller KH, Kraehenmann R, Vollenweider FX. Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. PMID 26875114 DOI: 10.1016/j.euroneuro.2016.01.005  0.96
2015 Bernasconi F, Kometer M, Pokorny T, Seifritz E, Vollenweider FX. The electrophysiological effects of the serotonin 1A receptor agonist buspirone in emotional face processing. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 25: 474-82. PMID 25637265 DOI: 10.1016/j.euroneuro.2015.01.009  0.56
2014 Schmid Y, Enzler F, Gasser P, Grouzmann E, Preller KH, Vollenweider FX, Brenneisen R, Müller F, Borgwardt S, Liechti ME. Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects. Biological Psychiatry. PMID 25575620 DOI: 10.1016/j.biopsych.2014.11.015  0.56
2014 Ort A, Kometer M, Rohde J, Seifritz E, Vollenweider FX. The role of GABAB receptors in human reinforcement learning. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 24: 1606-14. PMID 25194227 DOI: 10.1016/j.euroneuro.2014.08.013  0.56
2014 Kraehenmann R, Preller KH, Scheidegger M, Pokorny T, Bosch OG, Seifritz E, Vollenweider FX. Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers. Biological Psychiatry. PMID 24882567 DOI: 10.1016/j.biopsych.2014.04.010  0.96
2014 Csomor PA, Preller KH, Geyer MA, Studerus E, Huber T, Vollenweider FX. Influence of aripiprazole, risperidone, and amisulpride on sensory and sensorimotor gating in healthy 'low and high gating' humans and relation to psychometry. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 39: 2485-96. PMID 24801767 DOI: 10.1038/npp.2014.102  0.56
2014 Bernasconi F, Schmidt A, Pokorny T, Kometer M, Seifritz E, Vollenweider FX. Spatiotemporal brain dynamics of emotional face processing modulations induced by the serotonin 1A/2A receptor agonist psilocybin. Cerebral Cortex (New York, N.Y. : 1991). 24: 3221-31. PMID 23861318 DOI: 10.1093/cercor/bht178  0.56
2013 Kometer M, Schmidt A, Jäncke L, Vollenweider FX. Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 33: 10544-51. PMID 23785166 DOI: 10.1523/JNEUROSCI.3007-12.2013  0.96
2013 Holstein DH, Vollenweider FX, Geyer MA, Csomor PA, Belser N, Eich D. Sensory and sensorimotor gating in adult attention-deficit/hyperactivity disorder (ADHD). Psychiatry Research. 205: 117-26. PMID 23017654 DOI: 10.1016/j.psychres.2012.08.013  0.96
2013 Preller KH, Ingold N, Hulka LM, Vonmoos M, Jenni D, Baumgartner MR, Vollenweider FX, Quednow BB. Increased sensorimotor gating in recreational and dependent cocaine users is modulated by craving and attention-deficit/hyperactivity disorder symptoms. Biological Psychiatry. 73: 225-34. PMID 22959126 DOI: 10.1016/j.biopsych.2012.08.003  0.96
2013 Schmidt A, Diaconescu AO, Kometer M, Friston KJ, Stephan KE, Vollenweider FX. Modeling ketamine effects on synaptic plasticity during the mismatch negativity. Cerebral Cortex (New York, N.Y. : 1991). 23: 2394-406. PMID 22875863 DOI: 10.1093/cercor/bhs238  0.96
2013 Schmidt A, Kometer M, Bachmann R, Seifritz E, Vollenweider F. The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions. Psychopharmacology. 225: 227-39. PMID 22836372 DOI: 10.1007/s00213-012-2811-0  0.96
2012 Kraehenmann R, Vollenweider FX, Seifritz E, Kometer M. Crowding deficits in the visual periphery of schizophrenia patients. Plos One. 7: e45884. PMID 23049884 DOI: 10.1371/journal.pone.0045884  0.96
2012 Kometer M, Schmidt A, Bachmann R, Studerus E, Seifritz E, Vollenweider FX. Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. Biological Psychiatry. 72: 898-906. PMID 22578254 DOI: 10.1016/j.biopsych.2012.04.005  0.96
2012 Studerus E, Gamma A, Kometer M, Vollenweider FX. Prediction of psilocybin response in healthy volunteers. Plos One. 7: e30800. PMID 22363492 DOI: 10.1371/journal.pone.0030800  0.96
2012 Schmidt A, Bachmann R, Kometer M, Csomor PA, Stephan KE, Seifritz E, Vollenweider FX. Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 37: 865-75. PMID 22030715 DOI: 10.1038/npp.2011.261  0.96
2012 Quednow BB, Treyer V, Hasler F, Dörig N, Wyss MT, Burger C, Rentsch KM, Westera G, Schubiger PA, Buck A, Vollenweider FX. Assessment of serotonin release capacity in the human brain using dexfenfluramine challenge and [18F]altanserin positron emission tomography. Neuroimage. 59: 3922-32. PMID 21996132 DOI: 10.1016/j.neuroimage.2011.09.045  0.96
2012 Quednow BB, Kometer M, Geyer MA, Vollenweider FX. Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 37: 630-40. PMID 21956447 DOI: 10.1038/npp.2011.228  0.96
2011 Holstein DH, Csomor PA, Geyer MA, Huber T, Brugger N, Studerus E, Vollenweider FX. The effects of sertindole on sensory gating, sensorimotor gating, and cognition in healthy volunteers. Journal of Psychopharmacology (Oxford, England). 25: 1600-13. PMID 21890590 DOI: 10.1177/0269881111415734  0.96
2011 Kometer M, Cahn BR, Andel D, Carter OL, Vollenweider FX. The 5-HT2A/1A agonist psilocybin disrupts modal object completion associated with visual hallucinations. Biological Psychiatry. 69: 399-406. PMID 21126732 DOI: 10.1016/j.biopsych.2010.10.002  0.96
2011 Studerus E, Kometer M, Hasler F, Vollenweider FX. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. Journal of Psychopharmacology (Oxford, England). 25: 1434-52. PMID 20855349 DOI: 10.1177/0269881110382466  0.96
2010 Studerus E, Gamma A, Vollenweider FX. Psychometric evaluation of the altered states of consciousness rating scale (OAV). Plos One. 5: e12412. PMID 20824211 DOI: 10.1371/journal.pone.0012412  0.96
2010 Vollenweider FX, Kometer M. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nature Reviews. Neuroscience. 11: 642-51. PMID 20717121 DOI: 10.1038/nrn2884  0.96
2010 Hysek CM, Vollenweider FX, Liechti ME. Effects of a beta-blocker on the cardiovascular response to MDMA (Ecstasy). Emergency Medicine Journal : Emj. 27: 586-9. PMID 20378736 DOI: 10.1136/emj.2009.079905  0.96
2010 Holstein DH, Vollenweider FX, Jäncke L, Schopper C, Csomor PA. P50 suppression, prepulse inhibition, and startle reactivity in the same patient cohort suffering from posttraumatic stress disorder. Journal of Affective Disorders. 126: 188-97. PMID 20347156 DOI: 10.1016/j.jad.2010.02.122  0.96
2010 Roser P, Vollenweider FX, Kawohl W. Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists. The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry. 11: 208-19. PMID 20218784 DOI: 10.3109/15622970801908047  0.96
2010 Hilti CC, Delko T, Orosz AT, Thomann K, Ludewig S, Geyer MA, Vollenweider FX, Feldon J, Cattapan-Ludewig K. Sustained attention and planning deficits but intact attentional set-shifting in neuroleptic-naïve first-episode schizophrenia patients. Neuropsychobiology. 61: 79-86. PMID 20016226 DOI: 10.1159/000265133  0.96
2010 Geyer MA, Nichols DE, Vollenweider FX. Serotonin-related psychedelic drugs Encyclopedia of Neuroscience. 731-738. DOI: 10.1016/B978-008045046-9.01160-8  0.96
2009 Quednow BB, Schmechtig A, Ettinger U, Petrovsky N, Collier DA, Vollenweider FX, Wagner M, Kumari V. Sensorimotor gating depends on polymorphisms of the serotonin-2A receptor and catechol-O-methyltransferase, but not on neuregulin-1 Arg38Gln genotype: a replication study. Biological Psychiatry. 66: 614-20. PMID 19545856 DOI: 10.1016/j.biopsych.2009.05.007  0.96
2009 Hasler F, Kuznetsova OF, Krasikova RN, Cservenyak T, Quednow BB, Vollenweider FX, Ametamey SM, Westera G. GMP-compliant radiosynthesis of [18F]altanserin and human plasma metabolite studies. Applied Radiation and Isotopes : Including Data, Instrumentation and Methods For Use in Agriculture, Industry and Medicine. 67: 598-601. PMID 19162492 DOI: 10.1016/j.apradiso.2008.12.007  0.96
2009 Hasler F, Studerus E, Lindner K, Ludewig S, Vollenweider FX. Investigation of serotonin-1A receptor function in the human psychopharmacology of MDMA. Journal of Psychopharmacology (Oxford, England). 23: 923-35. PMID 18635693 DOI: 10.1177/0269881108094650  0.96
2009 Csomor PA, Yee BK, Feldon J, Theodoridou A, Studerus E, Vollenweider FX. Impaired prepulse inhibition and prepulse-elicited reactivity but intact reflex circuit excitability in unmedicated schizophrenia patients: a comparison with healthy subjects and medicated schizophrenia patients. Schizophrenia Bulletin. 35: 244-55. PMID 18245063 DOI: 10.1093/schbul/sbm146  0.96
2008 Geyer MA, Vollenweider FX. Serotonin research: contributions to understanding psychoses. Trends in Pharmacological Sciences. 29: 445-53. PMID 19086254 DOI: 10.1016/j.tips.2008.06.006  0.96
2008 Csomor PA, Yee BK, Vollenweider FX, Feldon J, Nicolet T, Quednow BB. On the influence of baseline startle reactivity on the indexation of prepulse inhibition. Behavioral Neuroscience. 122: 885-900. PMID 18729642 DOI: 10.1037/0735-7044.122.4.885  0.96
2008 Wackermann J, Wittmann M, Hasler F, Vollenweider FX. Effects of varied doses of psilocybin on time interval reproduction in human subjects. Neuroscience Letters. 435: 51-5. PMID 18325673 DOI: 10.1016/j.neulet.2008.02.006  0.96
2008 Cattapan-Ludewig K, Ludewig S, Messerli N, Vollenweider FX, Seitz A, Feldon J, Paulus MP. Decision-making dysregulation in first-episode schizophrenia. The Journal of Nervous and Mental Disease. 196: 157-60. PMID 18277225 DOI: 10.1097/NMD.0b013e318162aa1b  0.96
2008 Quednow BB, Csomor PA, Chmiel J, Beck T, Vollenweider FX. Sensorimotor gating and attentional set-shifting are improved by the mu-opioid receptor agonist morphine in healthy human volunteers. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 11: 655-69. PMID 18272020 DOI: 10.1017/S1461145707008322  0.96
2008 Csomor PA, Stadler RR, Feldon J, Yee BK, Geyer MA, Vollenweider FX. Haloperidol differentially modulates prepulse inhibition and p50 suppression in healthy humans stratified for low and high gating levels. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 33: 497-512. PMID 17460616 DOI: 10.1038/sj.npp.1301421  0.96
2007 Carter OL, Hasler F, Pettigrew JD, Wallis GM, Liu GB, Vollenweider FX. Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans. Psychopharmacology. 195: 415-24. PMID 17874073 DOI: 10.1007/s00213-007-0930-9  0.96
2007 Vollenweider FX, Csomor PA, Knappe B, Geyer MA, Quednow BB. The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 32: 1876-87. PMID 17299516 DOI: 10.1038/sj.npp.1301324  0.96
2007 Wittmann M, Carter O, Hasler F, Cahn BR, Grimberg U, Spring P, Hell D, Flohr H, Vollenweider FX. Effects of psilocybin on time perception and temporal control of behaviour in humans. Journal of Psychopharmacology (Oxford, England). 21: 50-64. PMID 16714323 DOI: 10.1177/0269881106065859  0.96
2006 Vollenweider FX, Barro M, Csomor PA, Feldon J. Clozapine enhances prepulse inhibition in healthy humans with low but not with high prepulse inhibition levels. Biological Psychiatry. 60: 597-603. PMID 16997001 DOI: 10.1016/j.biopsych.2006.03.058  0.96
2006 Csomor PA, Yee BK, Quednow BB, Stadler RR, Feldon J, Vollenweider FX. The monotonic dependency of prepulse inhibition of the acoustic startle reflex on the intensity of the startle-eliciting stimulus. Behavioural Brain Research. 174: 143-50. PMID 16935356 DOI: 10.1016/j.bbr.2006.07.016  0.96
2005 Carter OL, Burr DC, Pettigrew JD, Wallis GM, Hasler F, Vollenweider FX. Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors. Journal of Cognitive Neuroscience. 17: 1497-508. PMID 16269092 DOI: 10.1162/089892905774597191  0.96
2005 Gamma A, Brandeis D, Brandeis R, Vollenweider FX. The P3 in 'ecstasy' polydrug users during response inhibition and execution. Journal of Psychopharmacology (Oxford, England). 19: 504-12. PMID 16166188 DOI: 10.1177/0269881105056535  0.96
2005 Cattapan-Ludewig K, Hilti CC, Ludewig S, Vollenweider FX, Feldon J. Rapid visual information processing in schizophrenic patients: the impact of cognitive load and duration of stimulus presentation. A pilot study. Neuropsychobiology. 52: 130-4. PMID 16110246 DOI: 10.1159/000087558  0.96
2005 Vollenweider FX, Liechti ME, Paulus MP. MDMA affects both error-rate dependent and independent aspects of decision-making in a two-choice prediction task. Journal of Psychopharmacology (Oxford, England). 19: 366-74. PMID 15982991 DOI: 10.1177/0269881105053287  0.96
2005 Csomor PA, Vollenweider FX, Feldon J, Yee BK. On the feasibility to detect and to quantify prepulse-elicited reaction in prepulse inhibition of the acoustic startle reflex in humans. Behavioural Brain Research. 162: 256-63. PMID 15970219 DOI: 10.1016/j.bbr.2005.03.020  0.96
2005 Carter OL, Pettigrew JD, Hasler F, Wallis GM, Liu GB, Hell D, Vollenweider FX. Modulating the rate and rhythmicity of perceptual rivalry alternations with the mixed 5-HT2A and 5-HT1A agonist psilocybin. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 30: 1154-62. PMID 15688092 DOI: 10.1038/sj.npp.1300621  0.96
2005 Ludewig S, Geyer MA, Ramseier M, Vollenweider FX, Rechsteiner E, Cattapan-Ludewig K. Information-processing deficits and cognitive dysfunction in panic disorder. Journal of Psychiatry & Neuroscience : Jpn. 30: 37-43. PMID 15644996  0.96
2004 Carter OL, Pettigrew JD, Burr DC, Alais D, Hasler F, Vollenweider FX. Psilocybin impairs high-level but not low-level motion perception. Neuroreport. 15: 1947-51. PMID 15305143 DOI: 10.1097/00001756-200408260-00023  0.96
2004 Gamma A, Lehmann D, Frei E, Iwata K, Pascual-Marqui RD, Vollenweider FX. Comparison of simultaneously recorded [H2(15)O]-PET and LORETA during cognitive and pharmacological activation. Human Brain Mapping. 22: 83-96. PMID 15108296 DOI: 10.1002/hbm.20015  0.96
2004 Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX. Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology. 172: 145-56. PMID 14615876 DOI: 10.1007/s00213-003-1640-6  0.96
2003 Ludewig S, Paulus MP, Ludewig K, Vollenweider FX. Decision-making strategies by panic disorder subjects are more sensitive to errors. Journal of Affective Disorders. 76: 183-9. PMID 12943948 DOI: 10.1016/S0165-0327(02)00089-7  0.96
2003 Ludewig K, Paulus MP, Vollenweider FX. Behavioural dysregulation of decision-making in deficit but not nondeficit schizophrenia patients. Psychiatry Research. 119: 293-306. PMID 12914900 DOI: 10.1016/S0165-1781(03)00103-3  0.96
2003 Ludewig K, Geyer MA, Vollenweider FX. Deficits in prepulse inhibition and habituation in never-medicated, first-episode schizophrenia. Biological Psychiatry. 54: 121-8. PMID 12873801 DOI: 10.1016/S0006-3223(02)01925-X  0.96
2003 Ludewig K, Ludewig S, Seitz A, Obrist M, Geyer MA, Vollenweider FX. The acoustic startle reflex and its modulation: effects of age and gender in humans. Biological Psychology. 63: 311-23. PMID 12853174 DOI: 10.1016/S0301-0511(03)00074-7  0.96
2003 Vollenweider FX, Vollenweider-Scherpenhuyzen MF. [Hallucinogens, amphetamines and entactogens]. Therapeutische Umschau. Revue ThéRapeutique. 60: 323-8. PMID 12848067  0.96
2003 Umbricht D, Vollenweider FX, Schmid L, Grübel C, Skrabo A, Huber T, Koller R. Effects of the 5-HT2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 28: 170-81. PMID 12496954 DOI: 10.1038/sj.npp.1300005  0.96
2002 Vollenweider FX, Liechti ME, Gamma A, Greer G, Geyer M. Acute psychological and neurophysiological effects of MDMA in humans. Journal of Psychoactive Drugs. 34: 171-84. PMID 12691207 DOI: 10.1080/02791072.2002.10399951  0.96
2002 Leumann L, Feldon J, Vollenweider FX, Ludewig K. Effects of typical and atypical antipsychotics on prepulse inhibition and latent inhibition in chronic schizophrenia. Biological Psychiatry. 52: 729-39. PMID 12372664 DOI: 10.1016/S0006-3223(02)01344-6  0.96
2002 Hasler F, Bourquin D, Brenneisen R, Vollenweider FX. Renal excretion profiles of psilocin following oral administration of psilocybin: a controlled study in man. Journal of Pharmaceutical and Biomedical Analysis. 30: 331-9. PMID 12191719 DOI: 10.1016/S0731-7085(02)00278-9  0.96
2002 Ludewig K, Vollenweider FX. Impaired sensorimotor gating in schizophrenia with deficit and with nondeficit syndrome. Swiss Medical Weekly. 132: 159-65. PMID 12070788  0.96
2002 Ludewig K, Geyer MA, Etzensberger M, Vollenweider FX. Stability of the acoustic startle reflex, prepulse inhibition, and habituation in schizophrenia. Schizophrenia Research. 55: 129-37. PMID 11955972 DOI: 10.1016/S0920-9964(01)00198-0  0.96
2002 Umbricht D, Koller R, Vollenweider FX, Schmid L. Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers. Biological Psychiatry. 51: 400-6. PMID 11904134 DOI: 10.1016/S0006-3223(01)01242-2  0.96
2002 Ludewig S, Ludewig K, Geyer MA, Hell D, Vollenweider FX. Prepulse inhibition deficits in patients with panic disorder. Depression and Anxiety. 15: 55-60. PMID 11891993 DOI: 10.1002/da.10026  0.96
2002 Schönbächler RD, Gucker PM, Arigoni M, Kneifel S, Vollenweider FX, Buck A, Burger C, Berthold T, Brühlmeier M, Schubiger PA, Ametamey SM. PET imaging of dopamine transporters in the human brain using [(11)C]-beta-CPPIT, a cocaine derivative lacking the 2 beta-ester function. Nuclear Medicine and Biology. 29: 19-27. PMID 11786272 DOI: 10.1016/S0969-8051(01)00271-2  0.96
2001 Liechti ME, Vollenweider FX. Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. Human Psychopharmacology. 16: 589-598. PMID 12404538 DOI: 10.1002/hup.348  0.96
2001 Vollenweider FX, Geyer MA. A systems model of altered consciousness: integrating natural and drug-induced psychoses. Brain Research Bulletin. 56: 495-507. PMID 11750795 DOI: 10.1016/S0361-9230(01)00646-3  0.96
2001 Leumann L, Sterchi D, Vollenweider F, Ludewig K, Früh H. A neural network approach to the acoustic startle reflex and prepulse inhibition Brain Research Bulletin. 56: 101-110. PMID 11704346 DOI: 10.1016/S0361-9230(01)00607-4  0.96
2001 Frei E, Gamma A, Pascual-Marqui R, Lehmann D, Hell D, Vollenweider FX. Localization of MDMA-induced brain activity in healthy volunteers using low resolution brain electromagnetic tomography (LORETA). Human Brain Mapping. 14: 152-65. PMID 11559960 DOI: 10.1002/hbm.1049  0.96
2001 Liechti ME, Gamma A, Vollenweider FX. Gender differences in the subjective effects of MDMA. Psychopharmacology. 154: 161-8. PMID 11314678 DOI: 10.1007/s002130000648  0.96
2001 Vollenweider FX, Jones RT, Baggott MJ. Caveat emptor: editors beware. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 24: 461-3. PMID 11310414 DOI: 10.1016/S0893-133X(00)00170-6  0.96
2001 Gamma A, Buck A, Berthold T, Vollenweider FX. No difference in brain activation during cognitive performance between ecstasy (3,4-methylenedioxymethamphetamine) users and control subjects: a [H2(15)O]-positron emission tomography study. Journal of Clinical Psychopharmacology. 21: 66-71. PMID 11199950 DOI: 10.1097/00004714-200102000-00012  0.96
2001 Liechti ME, Geyer MA, Hell D, Vollenweider FX. Effects of MDMA (ecstasy) on prepulse inhibition and habituation of startle in humans after pretreatment with citalopram, haloperidol, or ketanserin. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 24: 240-52. PMID 11166515 DOI: 10.1016/S0893-133X(00)00199-8  0.96
2000 Umbricht D, Schmid L, Koller R, Vollenweider FX, Hell D, Javitt DC. Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Archives of General Psychiatry. 57: 1139-47. PMID 11115327  0.96
2000 Liechti ME, Vollenweider FX. The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine ('Ecstasy') in healthy volunteers. Journal of Psychopharmacology (Oxford, England). 14: 269-74. PMID 11106307  0.96
2000 Vollenweider-Scherpenhuyzen MF, Vollenweider FX. [Emergencies due to drug abuse]. Der Internist. 41: 886-98. PMID 11006876 DOI: 10.1007/s001080050641  0.96
2000 Liechti ME, Saur MR, Gamma A, Hell D, Vollenweider FX. Psychological and physiological effects of MDMA ("Ecstasy") after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 23: 396-404. PMID 10989266 DOI: 10.1016/S0893-133X(00)00126-3  0.96
2000 Gamma A, Buck A, Berthold T, Liechti ME, Vollenweider FX, Hell D. 3,4-Methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by [H(2)(15)O]-PET in healthy humans. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 23: 388-95. PMID 10989265 DOI: 10.1016/S0893-133X(00)00130-5  0.96
2000 Liechti ME, Vollenweider FX. Acute psychological and physiological effects of MDMA ("Ecstasy") after haloperidol pretreatment in healthy humans. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 10: 289-95. PMID 10871712  0.96
2000 Liechti ME, Baumann C, Gamma A, Vollenweider FX. Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 22: 513-21. PMID 10731626 DOI: 10.1016/S0893-133X(99)00148-7  0.96
2000 Buck A, Gucker PM, Schönbächler RD, Arigoni M, Kneifel S, Vollenweider FX, Ametamey SM, Burger C. Evaluation of serotonergic transporters using PET and [11C](+)McN-5652: assessment of methods. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 20: 253-62. PMID 10698061 DOI: 10.1097/00004647-200002000-00005  0.96
2000 Vollenweider FX, Vontobel P, Oye I, Hell D, Leenders KL. Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans. Journal of Psychiatric Research. 34: 35-43. PMID 10696831 DOI: 10.1016/S0022-3956(99)00031-X  0.96
2000 Gamma A, Frei E, Lehmann D, Pascual-Marqui RD, Hell D, Vollenweider FX. Mood state and brain electric activity in ecstasy users. Neuroreport. 11: 157-62. PMID 10683849  0.96
1999 Vollenweider FX, Gamma A, Liechti M, Huber T. Is a single dose of MDMA harmless? Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 21: 598-600. PMID 10481844 DOI: 10.1016/S0893-133X(99)00032-9  0.96
1999 Vollenweider FX, Remensberger S, Hell D, Geyer MA. Opposite effects of 3,4-methylenedioxymethamphetamine (MDMA) on sensorimotor gating in rats versus healthy humans. Psychopharmacology. 143: 365-72. PMID 10367553 DOI: 10.1007/s002130050960  0.96
1999 Vollenweider FX, Vontobel P, Hell D, Leenders KL. 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man--a PET study with [11C]raclopride. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 20: 424-33. PMID 10192823 DOI: 10.1016/S0893-133X(98)00108-0  0.96
1999 Zessin J, Gucker P, Ametamey SM, Steinbach J, Brust P, Vollenweider FX, Johannsen B, Schubiger PA. Efficient synthesis of enantiomerically pure thioester precursors of [11C]McN-5652 from racemic McN-5652 Journal of Labelled Compounds and Radiopharmaceuticals. 42: 1301-1312. DOI: 10.1002/(SICI)1099-1344(19991230)42:13<1301::AID-JLCR298>3.0.CO;2-2  0.96
1998 Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport. 9: 3897-902. PMID 9875725  0.96
1998 Vollenweider-Scherpenhuyzen MF, Vollenweider FX. [The drug emergency]. Der Anaesthesist. 47: 946-55. PMID 9870095 DOI: 10.1007/s001010050650  0.96
1998 Vollenweider FX, Maguire RP, Leenders KL, Mathys K, Angst J. Effects of high amphetamine dose on mood and cerebral glucose metabolism in normal volunteers using positron emission tomography (PET). Psychiatry Research. 83: 149-62. PMID 9849724 DOI: 10.1016/S0925-4927(98)00033-X  0.96
1998 Vollenweider FX. Advances and pathophysiological models of hallucinogenic drug actions in humans: a preamble to schizophrenia research. Pharmacopsychiatry. 31: 92-103. PMID 9754840 DOI: 10.1055/s-2007-979353  0.96
1998 Vollenweider FX, Gamma A, Liechti M, Huber T. Psychological and cardiovascular effects and short-term sequelae of MDMA ("ecstasy") in MDMA-naïve healthy volunteers. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 19: 241-51. PMID 9718588 DOI: 10.1016/S0893-133X(98)00013-X  0.96
1998 Ametamey S, Vollenweider FX, Patt J, Bourquin D, Hasler F, Beer HF, Schubiger PA. 11C-Radiolabeling of hallucinogenic psilocin, a potential radioligand for studying the role of serotonin receptors in psychotic symptom formation Journal of Labelled Compounds and Radiopharmaceuticals. 41: 585-594. DOI: 10.1002/(SICI)1099-1344(199807)41:7<585::AID-JLCR115>3.0.CO;2-U  0.96
1997 Hasler F, Bourquin D, Brenneisen R, Bär T, Vollenweider FX. Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man. Pharmaceutica Acta Helvetiae. 72: 175-84. PMID 9204776 DOI: 10.1016/S0031-6865(97)00014-9  0.96
1997 Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 16: 357-72. PMID 9109107 DOI: 10.1016/S0893-133X(96)00246-1  0.96
1997 Vollenweider FX, Leenders KL, Oye I, Hell D, Angst J. Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 7: 25-38. PMID 9088882 DOI: 10.1016/S0924-977X(96)00042-9  0.96
1997 Vollenweider FX, Leenders KL, Scharfetter C, Antonini A, Maguire P, Missimer J, Angst J. Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG). European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 7: 9-24. PMID 9088881 DOI: 10.1016/S0924-977X(96)00039-9  0.96
1995 Feng N, Vollenweider FX, Minder EI, Rentsch K, Grampp T, Vonderschmitt DJ. Development of a gas chromatography-mass spectrometry method for determination of ketamine in plasma and its application to human samples. Therapeutic Drug Monitoring. 17: 95-100. PMID 7725385  0.96
1994 Vollenweider FX, Scharfetter C, Leenders KL, Angst J. Disturbance of serotonergic or glutamatergic neurotransmission results in hyperfrontality as measured by PET and FDG in acute human model psychoses European Neuropsychopharmacology. 4: 367. DOI: 10.1016/0924-977X(94)90190-2  0.96
1992 Vollenweider FX. The use of psychotomimetics in schizophrenia research with special amphasis on the PCP/ketamine model psychosis | DIE ANWENDUNG VON PSYCHOTOMIMETIKA IN DER SCHIZOPHRENIEFORSCHUNG UNTER BESONDERER BERUCKSICHTIGUNG DER KETAMIN/PCP-MODELL-PSYCHOSE Sucht. 38: 398-409.  0.96
1992 Vollenweider FX. The use of psychedelic agents in schizophrenia research with special reference to the ketamine/PCP model psychosis: Preliminary results of a PET study by means of fluorodeoxyglucose F18 in healthy probands | DIE ANWENDUNG VON PSYCHOTOMIMETIKA IN DER SCHIZOPHRENIEFORSCHUNG UNTER BESONDERER BERUCKSICHTIGUNG DER KETAMIN/PCP MODELL-PSYCHOSE: VORLAUFIGE RESULTATE EINER PET (POSITRONEN-EMISSIONS-TOMOGRAPHIE)-STUDIE MITTELS (18F)-FLUORODEOXYGLUKOSE BEI GESUNDEN PROBANDEN Sucht. 38: 117-118.  0.96
1991 Do KQ, Vollenweider FX, Zollinger M, Cuénod M. Effect of Climbing Fibre Deprivation on the K+-evoked Release of Endogenous Adenosine from Rat Cerebellar Slices. The European Journal of Neuroscience. 3: 201-208. PMID 12106218  0.96
Show low-probability matches.